Opdualag Approved for Unresectable, Metastatic Melanoma
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.
Results from a randomized trial neither support nor rule out the possibility that aspirin might have a chemopreventive effect on melanoma incidence.
From 2017 to 2019, increase seen in use of adjuvant systemic therapy, with variation in use among treating centers
The largest declines in incidence were seen for cervical, endocrine, and prostate cancers, as well as melanoma.
Higher intake of dietary fiber linked to longer progression-free survival in melanoma patients on immune checkpoint blockade
Researchers found that entry into the ventricle space during surgical resection elevated the risk of leptomeningeal disease in patients with melanoma brain metastases.
Medical and clinical oncologists were more likely than neurosurgeons and radiation oncologists to recommend systemic therapy alone.
FDA-approved drug therapies for cutaneous melanoma.
A review of dermatological adverse events associated with anti-glaucoma eye drop is provided.
Combination provides greater benefit than nivolumab alone for progression-free survival in untreated metastatic or unresectable melanoma